Introduction 

For most of the twentieth century, the question of how to treat cancer had a short answer surgery, radiation, and chemotherapy. That answer was not wrong chemotherapy has saved millions of lives and remains a cornerstone of cancer care. But it is no longer the whole answer. Immunotherapy has changed the landscape of oncology more fundamentally than any development since the introduction of cytotoxic drugs and chemotherapy, and the question is now one that oncologists, patients, and families genuinely need to understand. The honest answer is not that one is better than the other. It is that each works better in specific contexts, both have real limitations, and the most effective treatment plans in 2026 increasingly involve using them together. This guide explains how each works, when each is preferred, and what patients should ask when choosing the right oncology hospital in Delhi NCR to help guide their decision. 

How Each Treatment Works 

Chemotherapy 

Chemotherapy uses cytotoxic drugs to kill rapidly dividing cells. Cancer cells divide more frequently than most normal cells, which is why they are preferentially targeted, but the mechanism is not selective. Bone marrow cells, hair follicles, and gastrointestinal epithelium all divide rapidly too, which is why hair loss, immunosuppression, mucositis, and nausea are characteristic side effects rather than incidental ones. Chemotherapy travels systemically, which makes it effective against cancer that has spread beyond a primary site but also means that its toxicity is distributed throughout the body. It works quickly tumour shrinkage can be documented within weeks, which makes it valuable when immediate disease control is required. 

Immunotherapy 

It works differently at the mechanism level rather than attacking cancer cells directly, it modifies the immune system's ability to recognise and eliminate them. Cancer cells commonly evade immune detection by expressing surface proteins, most notably PD-L1 that suppress T-cell activity at the point of contact. Checkpoint inhibitors block this suppression, restoring T-cell function. CAR-T cell therapy takes a more direct engineering approach, extracting a patient's T-cells and genetically modifying them to recognise a tumour antigen and reinfuse it. Monoclonal antibodies can tag cancer cells for immune destruction or deliver cytotoxic payloads directly to them. The common thread is that immunotherapy recruits or augments the body's own defences rather than substituting a chemical attack for them. 

Chemotherapy vs Immunotherapy: Key Differences at a Glance 

• Mechanism: Chemotherapy kills dividing cells directly, immunotherapy activates or engineers immune responses. 

• Side effect profile: Chemotherapy produces broad systemic toxicity, immunotherapy produces immune-related adverse events that require different management 

• Speed of response: Chemotherapy typically faster, immunotherapy may take weeks to months and requires different response assessment criteria 

• Durability: Chemotherapy responses often time-limited, immunotherapy can produce multi-year remissions in responding patients 

• Biomarker dependency: Chemotherapy has limited predictive biomarkers, immunotherapy effectiveness is strongly linked to PD-L1, TMB, and MSI status 

• Best established in: Chemotherapy most solid tumours and haematological cancers; immunotherapy melanoma, NSCLC, bladder, renal, and MSI-H tumours 

When Chemotherapy Is the Right Choice 

Chemotherapy remains the preferred front-line approach when rapid tumour reduction is required a large mediastinal mass causing airway compromise, for example, does not allow time for an immune response to build. It is also the standard of care in cancer types where immunotherapy has not yet demonstrated meaningful benefit, such as small cell lung cancer outside first-line pembrolizumab combinations, most pancreatic adenocarcinomas, and several gynaecological cancers. In adjuvant settings, reducing recurrence risk after surgical resection, chemotherapy protocols have decades of outcome data behind them. In haematological malignancies, specific regimens are integrated with stem cell transplantation in ways that are not replaceable by current immunotherapy approaches. 

When Immunotherapy Is the Right Choice 

It produces its most impressive results in tumours with specific biomarker profiles: high PD-L1 expression, high tumour mutational burden (TMB-H), or microsatellite instability (MSI-H), all of which indicate tumours that are more likely to be recognised by an activated immune system. Pembrolizumab monotherapy in PD-L1 high non-small cell lung cancer, nivolumab in melanoma, and CAR-T therapy in relapsed/refractory large B-cell lymphoma represent the strongest efficacy data. The durable remissions are achievable some patients with stage IV melanoma remain disease-free years after stopping treatment, representing outcomes that cytotoxic chemotherapy alone does not reliably produce. Immunotherapy is also preferable when minimising treatment-related side effects is a priority for quality of life reasons. 

The Real Answer in 2026: Combination Approaches 

The framing of chemotherapy vs immunotherapy as an either or choice increasingly misrepresents how treatment decisions are made. The most significant recent advances in lung, breast, bladder, and gastrointestinal cancer have come from combining both modalities chemotherapy to debulk disease rapidly and reduce immunosuppressive tumour microenvironment factors and immunotherapy to establish durable disease control. Neoadjuvant combinations are showing pathological complete response rates in breast cancer that neither treatment achieves alone. Maintenance immunotherapy after platinum-based chemotherapy has become standard in several settings. The practical implication is that the question patients should bring to their oncologist is not "which one" but "what combination, in what sequence, based on my tumour's biology". 

The Role of Biomarker Testing 

Choosing between or combining these treatments without biomarker data is clinical guesswork. Molecular profiling, PD-L1 immunohistochemistry, next-generation sequencing for TMB and MSI status, and tumour-specific genomic panels determine which treatment is likely to work and which is not. Centres offering advanced cancer treatment in India at a specialist level now integrate molecular diagnostics as a standard pre-treatment step, rather than as an optional investigation. This matters practically: a patient with MSI-H colorectal cancer is an excellent candidate for checkpoint inhibitor monotherapy; the same patient without that marker should not receive immunotherapy as sole treatment. Getting the biomarker workup done is not a bureaucratic process it is the clinical foundation on which the entire treatment decision rests. 

Why Specialist Centre Selection Matters 

Access to combination therapies, clinical trials, and molecular diagnostics is not uniform across oncology facilities. A dedicated oncology hospital with a multidisciplinary tumour board provides treatment decisions that reflect current evidence and individual patient biology. What to look for: 

• Reflex molecular profiling as a standard pre-treatment protocol, not an optional add-on 

• Active clinical trial portfolio many of the most effective 2026 combination regimens are still trial-access only 

• Dedicated immune-related adverse event management checkpoint inhibitor toxicity requires specialist recognition and treatment 

• Tumour board composition that includes medical oncology, radiation oncology, surgical oncology, and pathology reviewing each complex case 

• Published outcomes by tumour type and stage advanced cancer treatment that is genuinely specialist-level will have outcome data to support that claim 

Expert Tips for Patients Navigating Treatment Decisions 

• Ask for molecular profiling before agreeing to any systemic treatment — PD-L1, MSI, and TMB status should be known before the treatment decision is finalised; starting without them risks receiving a suboptimal regimen. 

• Understand that immunotherapy side effects are different, not fewer — immune-related adverse events, including colitis, pneumonitis, hepatitis, and thyroiditis, are less predictable than chemotherapy side effects and require prompt recognition; ask your oncology team what to watch for and when to call. 

• Do not interpret initial progression on immunotherapy as treatment failure — Pseudoprogression, where tumours appear to grow before shrinking, is a documented phenomenon with checkpoint inhibitors; response assessment timelines differ from chemotherapy. 

• Ask specifically about clinical trials at your initial consultation — many of the most effective combination regimens in 2026 are available through trials; a centre that does not raise this option may not have the infrastructure to offer it. 

• Request a multidisciplinary tumour board review — treatment decisions reviewed by a full MDT produce better-aligned plans than single-specialist recommendations, particularly for complex or unusual presentations. 

• Discuss the financial and logistical aspects of immunotherapy early — checkpoint inhibitors are significantly pricier than most chemotherapy regimens; understanding insurance coverage and hospital support programmes before starting avoids mid-treatment financial crises. 

• Choose an oncology hospital based on MDT composition and trial access — not proximity or reputation alone; ask specifically about how often the tumour board meets, molecular testing capability, and which trials are currently open. 

Conclusion 

The chemotherapy and immunotherapy question does not have a single answer because cancer is not a single disease and patients are not interchangeable. What the evidence in 2026 clearly shows is that immunotherapy has transformed outcomes in specific cancer types, that combination approaches are the direction in which most clinical development is heading, and that biomarker-guided treatment selection separates effective personalised care from generalised protocols. Accessing advanced cancer treatment at a specialist level means accessing all of this the diagnostics, the treatment options, the clinical trial infrastructure, and the multidisciplinary expertise. For expert oncology evaluation and a treatment plan built on current evidence, consult experienced specialists at a trusted oncology hospital in Delhi NCR because the quality of the treatment decision made at the start shapes everything that follows.